Precision BioSciences recap highlights ARCUS cccDNA elimination and 2028 cash runway
Precision BioSciences said its ARCUS platform supports PBGENE—HBV and PBGENE—DMD, citing durable cccDNA elimination and improved safety seen in HBGENE data, a cash runway into 2028, regulatory designations, and progress including initial PBGENE—DMD dosing and safety.